Welcome to our dedicated page for Arcadia Bioscien SEC filings (Ticker: RKDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcadia Biosciences, Inc. filings document the company's plant-based products business, operating results, governance matters, and capital structure. Its 8-K reports cover material agreements, inducement transactions involving preferred investment options and common stock, shareholder voting matters, board changes, and changes in the company's independent registered public accounting firm.
Arcadia's proxy and periodic disclosures address executive compensation, board governance, internal control over financial reporting, going-concern risk language, and other risks associated with recurring losses, cash use, financing needs, and public-company compliance.
Arcadia Biosciences, Inc. filed a current report to furnish its financial results for the second quarter ended June 30, 2025. The company issued a press release and detailed financial information, attached as Exhibits 99.1 and 99.2, covering second-quarter 2025 performance and business highlights.
The report also reiterates the previously announced plan for an all-stock exchange transaction with Roosevelt Resources, LP under a Securities Exchange Agreement. Arcadia has filed a Registration Statement on Form S-4, including a preliminary proxy statement/prospectus, and a pre-effective amendment filed on July 31, 2025. After the Registration Statement is declared effective, Arcadia intends to mail a definitive proxy statement/prospectus to stockholders for a vote on the proposed transaction.